Phenylalanine & Tryosine, Blood

Total Page：16

File Type：pdf, Size：1020Kb

Lab Dept: Chemistry Test Name: PHENYLALANINE & TYROSINE, BLOOD General Information Lab Order Codes: PHTY Synonyms: Phenylketonuria (PKU) CPT Codes: 84510 – Tyrosine 84030 – Phenylalanine (PKU), blood Test Includes: Phenylalanine and Tyrosine reported in mg/dL Logistics Test Indications: Useful in diagnosis of phenylketonuria (PKU) and to monitor phenylalanine and tyrosine levels in PKU patients on low phenylalanine diets. Lab Testing Sections: Serology – Sendouts Referred to: Fairview University Medical Center (Test code: TYPH) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6500 Test Availability: Daily, 24 hours and performed on the following schedule at Fairview. All specimens will be processed and held to be run on these days: Mondays and Wednesdays, results are reported the following day. Turnaround Time: 2 – 5 days Special Instructions: N/A Specimen Specimen Type: Blood Container: Green top (Li Heparin) tube Alternate: Green(NaHep or LiHep NO GEL) tube, Lavender top (EDTA) tube or Red top (NO GEL) or filter paper. Draw Volume: 2 mL blood (Minimum: 0.3 mL) or blood absorbed onto filter paper. Processed Volume: 1 mL (Minimum: 0.05 mL) plasma/serum Collection: Routine venipuncture Special Processing: Lab Staff: Centrifuge specimen, remove serum/plasma aliquot into a screw- capped round bottom plastic vial. Store and ship at room temperature. Forward promptly. Patient Preparation: None Sample Rejection: Mislabeled or unlabeled specimens Interpretive Reference Range: Phenylalanine: Age: Result (mg/dL): 0 – 3 months: 0.0 - 1.9 mg/dL 4 months – 11 years: 0.1 - 1.4 mg/dL > or = 12 years: 0.5 - 1.6 mg/dL Tyrosine Age: Result (mg/dL): 0 – 3 months: 0.0 - 2.7 mg/dL 4 months – 11 years: 0.4 - 1.6 mg/dL > or = 12 years: 0.6 - 2.4 mg/dL Critical Values: N/A Limitations: N/A Methodology: High performance ion exchange liquid chromatography. References: Fairview University Medical Center December 2017 .

Copy Link

Recommended publications

Discovery of Small Molecule and Peptide-Based Ligands for the Methyl-Lysine Binding Proteins 53Bp1 and Phf1/Phf19
DISCOVERY OF SMALL MOLECULE AND PEPTIDE-BASED LIGANDS FOR THE METHYL-LYSINE BINDING PROTEINS 53BP1 AND PHF1/PHF19 Michael Thomas Perfetti A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Division of Chemical Biology and Medicinal Chemistry in the Doctoral Program of the UNC Eshelman School of Pharmacy. Chapel Hill 2015 Approved by: Stephen Frye David Lawrence Albert Bowers Brian Strahl Greg Gang Wang Andrew Lee © 2015 Michael Thomas Perfetti ALL RIGHTS RESERVED ii ABSTRACT Michael Thomas Perfetti: Discovery of Small Molecule and Peptide-based Ligands for the Methyl-Lysine Binding Proteins 53BP1 and PHF1/PHF19 (Under the direction of Stephen V. Frye) Improving the understanding of the role of chromatin regulators in the initiation, development, and suppression of cancer and other devastating diseases is critical, as they are integral players in the regulation of DNA integrity and gene expression. Developing chemical tools for histone binding proteins that possess cellular activity will allow for further elucidation of the specific function of this class of histone regulating proteins. This research specifically targeted two different classes of Tudor domain containing histone binding proteins that are directly involved in the DNA damage response and modulation of gene transcription activities. The first methyl-lysine binding protein targeted was 53BP1, which is a DNA damage response protein. 53BP1 uses a tandem tudor domain (TTD) to recognize histone H4 dimethylated on lysine 20 (H4K20me2), a post-translational modification (PTM) induced by double-strand DNA breaks.
[Show full text]
Synthesis of Isothiocyanates Using DMT/NMM/Tso− As a New Desulfurization Reagent
molecules Article Synthesis of Isothiocyanates Using DMT/NMM/TsO− as a New Desulfurization Reagent Łukasz Janczewski 1,* , Dorota Kr˛egiel 2 and Beata Kolesi ´nska 1 1 Faculty of Chemistry, Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland; [email protected] 2 Department of Environmental Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Wolczanska 171/173, 90-924 Lodz, Poland; [email protected] * Correspondence: [email protected] Abstract: Thirty-three alkyl and aryl isothiocyanates, as well as isothiocyanate derivatives from esters of coded amino acids and from esters of unnatural amino acids (6-aminocaproic, 4-(aminomethyl)benzoic, and tranexamic acids), were synthesized with satisfactory or very good yields (25–97%). Synthesis was performed in a “one-pot”, two-step procedure, in the presence of organic base (Et3N, DBU or NMM), and carbon disulfide via dithiocarbamates, with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4- methylmorpholinium toluene-4-sulfonate (DMT/NMM/TsO−) as a desulfurization reagent. For the synthesis of aliphatic and aromatic isothiocyanates, reactions were carried out in a microwave reactor, and selected alkyl isothiocyanates were also synthesized in aqueous medium with high yields (72–96%). Isothiocyanate derivatives of L- and D-amino acid methyl esters were synthesized, under conditions without microwave radiation assistance, with low racemization (er 99 > 1), and their absolute configuration was confirmed by circular dichroism. Isothiocyanate derivatives of natural and unnatural amino acids were evaluated for antibacterial activity on E. coli and S. aureus bacterial strains, where the Citation: Janczewski, Ł.; Kr˛egiel,D.; most active was ITC 9e.
[Show full text]
The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting
Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
[Show full text]
Specificity of the Antibody Receptor Site to D-Lysergamide
Proc. Nat. Acad. Sci. USA Vol. 68, No. 7, pp. 1483-1487, July 1971 Specificity of the Antibody Receptor Site to D-Lysergamide: Model of a Physiological Receptor for Lysergic Acid Diethylamide (molecular structure/hallucinogenic/rabbit/guinea pig/psychotomimetic) HELEN VAN VUNAKIS, JOHN T. FARROW, HILDA B. GJIKA, AND LAWRENCE LEVINE Graduate Department of Biochemistry, Brandeis University, Waltham, Massachusetts 02154 Commnunicated by Francis 0. Schmitt, April 21, 1971 ABSTRACT Antibodies to D-lysergic acid have been amine, and NN-dimethyl-3,4,5-trimethoxyphenylethylamine produced in rabbits and guinea pigs and a radioimmuno- were the generous gifts of Dr. W. E. Scott of Hoffmann-La assay for the hapten was developed. The specificity of this Iysergamide-antilysergamide reaction was determined by Roche. DOM (2,5-dimethoxy-4-methylamphetamine) was competitive binding with unlabeled lysergic acid diethyl- given to us by Dr. S. H. Snyder of Johns Hopkins Univer- amnide (LSD), psychotomimetic drugs, neurotransmitters, sity. Sandoz Pharmaceuticals provided us with ergonovine, and other compounds with diverse structures. LSD and methylergonovine, ergosine, and ergotomine. LSD tartarate several related ergot alkaloids were potent competitors, three to seven times more potent than lysergic acid itself. powder (Sandoz Batch no. 98601) and psilocybin powder The NN-dimethyl derivatives of several compounds, in- (Sandoz Batch no. 55001) were provided by the U.S. Food and cluding tryptamine, 5-hydroxytryptamine, 4-hydroxy- Drug Administration and the National Institute of Mental tryptamine, 5-methoxytryptamine, tyramine, and mesca- Health. line, were only about ten times less effective than lysergic Psilocin was obtained by dephosphorylating psilocybin acid, even though these compounds lack some of the ring systems of lysergic acid.
[Show full text]
Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
[Show full text]
Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci
(19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
[Show full text]
Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: a PET/ [11C]Raclopride Study in Healthy Men
Neuropsychopharmacology (2004) 29, 427–432 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: A PET/ [11C]Raclopride Study in Healthy Men 1,2, 2 2 1 3 2 Marco Leyton *, Alain Dagher , Isabelle Boileau , Kevin Casey , Glen B Baker , Mirko Diksic , Roger 2 1 1,2 Gunn , Simon N Young and Chawki Benkelfat 1 2 Department of Psychiatry, McGill University, Montre´al, Que´bec, Canada; Department of Neurology & Neurosurgery, McGill University, 3 Montre´al, Que´bec, Canada; Department of Psychiatry, Mackenzie Centre, University of Alberta, Edmonton, Alberta, Canada Acute phenylalanine/tyrosine depletion (APTD) has been proposed as a new method to decrease catecholamine neurotransmission safely, rapidly, and transiently. Validation studies in animals are encouraging, but direct evidence in human brain is lacking. In the present study, we tested the hypothesis that APTD would reduce stimulated dopamine (DA) release, as assessed by positron emission 11 tomography (PET) and changes in [ C]raclopride binding potential (BP), a measure of DA D2/D3 receptor availability. Eight healthy men 11 received two PET scans, both following d-amphetamine, 0.3 mg/kg, p.o., an oral dose known to decrease [ C]raclopride BP in ventral striatum. On the morning before each scan, subjects ingested, in counter-balanced order, an amino-acid mixture deficient in the catecholamine precursors, phenylalanine, and tyrosine, or a nutritionally balanced mixture. Brain parametric images were generated by calculating [11C]raclopride BP at each voxel. BP values were extracted from the t-map (threshold: t ¼ 4.2, equivalent to p 0.05, o Bonferroni corrected) and a priori identified regions of interest from each individual’s coregistered magnetic resonance images.
[Show full text]
Ebinder, Reply Comment on Proposed Amendment Sand Issue
UNITED STATES DISTRICT COURT Northern District of New York 206 Federal Building 15 Henry Street Binghamton, New York 13902 Thomas J. McAvoy Senior District Judge January 3, 2017 United States Sentencing Commission One Columbus Circle, N.E. Suite 2-500 Washington, DC 2002-8002 Attention: Public Affairs To the Sentencing Commission: I write in reference to your recent request for public comment on sentencing issues involving MDMA/Ecstasy, synthetic cannabinoids (such as JWH-018 and AM-2201), and synthetic cathinones (such as Methylone, MDPV, and Mephedrone). I currently preside over a case involving methylone distribution. The Defendant retained an expert who produced a report concerning the appropriate marijuana equivalency for methylone. The government responded to that report. After considering those documents, I obtained the report of an independent expert chemist. That expert addressed the questions of substantial similarity as required by USSG '2D1.1. I would be happy to share those reports and the briefs and filings related to them with the Commission. Please contact my law clerk at the address below if you would like to have those documents forwarded to you. Sincerely, Case 1:14-cr-00232-TJM Document 53 Filed 05/24/16 Page 1 of 2 May 24, 2016 via ELECTRONIC FILING Senior Judge Thomas J. McAvoy United States District Court Northern District of New York James T. Foley Courthouse 445 Broadway Albany, New York 12207 Re: United States v. Douglas Marshall, et al Docket: 14-CR-232 Your Honor: As you are aware, this firm represents defendant Douglas Marshall in connection with the above-referenced case.
[Show full text]
Leathen Thesis
The Development of Reactions for the Stereoselective Synthesis of Heterocycles and Benzylic Amines, and Exploration of Bisisoxazolidines as Small Molecule Transcriptional Activation Domains by Matthew L. Leathen A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Chemistry) in The University of Michigan 2011 Doctoral Committee: Associate Professor John P. Wolfe, Chair Professor Anna K. Mapp Assistant Professor Garry D. Dotson Assistant Professor Pavel Nagorny Matthew L. Leathen 2011 Dedication To My Family ii Table of Contents Dedication .......................................................................................................................... ii List of Figures ................................................................................................................... vi List of Tables .................................................................................................................. viii List of Schemes ................................................................................................................. ix List of Abbreviations ........................................................................................................ x Abstract……… ............................................................................................................... xiv Chapter 1 Introduction..................................................................................................... 1 1.1 Importance of Alkaloids and Nitrogen-Containing
[Show full text]
4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 4.3
4-Fluoroamphetamine (4-FA) Critical Review Report Agenda Item 4.3 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 4.3 4-FA Contents Acknowledgements.................................................................................................................................. 4 Summary...................................................................................................................................................... 5 1. Substance identification ....................................................................................................................... 6 A. International Nonproprietary Name (INN).......................................................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 6 C. Other Chemical Names ................................................................................................................................................... 6 D. Trade Names ....................................................................................................................................................................... 6 E. Street Names ....................................................................................................................................................................... 6 F. Physical Appearance ......................................................................................................................................................
[Show full text]
Rubiscolins Are Naturally Occurring G Protein-Biased Delta Opioid Receptor Peptides
European Neuropsychopharmacology (2019) 29, 450–456 www.elsevier.com/locate/euroneuro SHORT COMMUNICATION Rubiscolins are naturally occurring G protein-biased delta opioid receptor peptides a , 1 a, 1 a Robert J. Cassell , Kendall L. Mores , Breanna L. Zerfas , a a, b , c a ,b , c Amr H. Mahmoud , Markus A. Lill , Darci J. Trader , a, b ,c , ∗ Richard M. van Rijn a Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA b Purdue Institute for Drug Discovery, West Lafayette, IN 47907, USA c Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907, USA Received 6 August 2018; received in revised form 19 November 2018; accepted 16 December 2018 KEYWORDS Abstract Delta opioid receptor; The impact that β-arrestin proteins have on G protein-coupled receptor trafficking, signaling Beta-arrestin; and physiological behavior has gained much appreciation over the past decade. A number of Natural products; studies have attributed the side effects associated with the use of naturally occurring and syn- Biased signaling; thetic opioids, such as respiratory depression and constipation, to excessive recruitment of Rubisco; β-arrestin. These findings have led to the development of biased opioid small molecule ago- G protein-coupled nists that do not recruit β-arrestin, activating only the canonical G protein pathway. Similar G receptor protein-biased small molecule opioids have been found to occur in nature, particularly within kratom, and opioids within salvia have served as a template for the synthesis of other G protein- biased opioids. Here, we present the first report of naturally occurring peptides that selectively activate G protein signaling pathways at δ opioid receptors, but with minimal β-arrestin recruit- ment.
[Show full text]
Georgia State Forensic Drugs
Comprehensive Forensic FT-IR Collection Library Listing – 4,286 spectra This extensive library contains materials not only of forensic interest but also for general problem solving and identification of unknown substances in industry and academia. The wide range of items include drugs, clandestine lab chemicals, explosives, paints, fabrics, dyes, polymers, inorganic compounds, pigments, adhesives, and other common materials. The library consists of 4,286 spectra that were acquired from a wide range of laboratories involved in forensic investigations. The collection includes the following classes of compounds: • Drugs of abuse, scheduled materials • Pharmaceuticals, vitamins and excipients • Clandestine lab materials and intermediates • Solvents, organic chemicals and hazardous chemicals • Accelerants • Lubricants and natural oils • Explosives, pyrotechnics, primers, powders and boosters • Herbal and plant material and fibers • Automobile paint vehicles, pigments, primers and clear coats • Textiles, natural and man-made fibers, carpet materials • Paints, coatings, varnishes, oils • Dyes and stains • Polymers, monomers, copolymers, plasticizers and rubbers • Inorganics, pigments, minerals and clays • Tape, adhesives, sealants, glues, caulks and putties • Crystal test derivatives and intermediates • Household chemicals, cleaning agents, surfactants and pesticide All spectra were measured using micro or macro Diamond ATR, thin films on salt windows or KBr pellets at 4 cm-1 spectral resolution. Comprehensive Forensic FT-IR Collection Index
[Show full text]